Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement

Back to the Newsroom Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement Friday, 28 August 2026 07:00 PM Topic: Company Update NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. (" Lobe " or the " Company ") ( CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE ), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce an upsize to its previously announced non-brokered private placement offering of common shares in the capital of the Company (" CommonShares ") at a price of $0.085 per Common Share (the " Private Placement "). The Company closed the first tranche of the Private Placement on August 19, 2026 (the " First Tranche ") through the issuance of 24,705,880 for gross proceeds of $2,100,000. As a result of further demand, the Company intends to close an additional tranche of the Private Placement (the " Second Tranche "), comprised of 705,882 Shares for gross proceeds of approximately $60,000. Assuming closing of the Second Tranche, the Company will have issued an aggregate of 25,411,762 Shares for gross proceeds of $2,160,000 pursuant to the Private Placement. The Company intends to use the proceeds of the Private Placement for working capital and general corporate purposes, and to advance its S-100 drug candidate for the treatment of sickle cell disease. A portion of the proceeds will be directed to its subsidiary, Applied Lipid Technologies, Inc., to support development of the S-100 program toward human clinical trials. The Company has procured the active pharmaceutical ingredient required for these studies, enabling the program to move forward. The Second Tranche remains subject to receipt of all necessary regulatory approvals, including acceptance by the Canadian Securities Exchange (the " Exchange "). All securities issued in connection with the Second Tranche will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. None of the securities sold under the Private Placement have been or will be registered under the United States Securities Act of 1933 , as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE. About Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF | Frankfurt: LOBE.F) Lobe Sciences Ltd. is a biopharmaceutical company advancing programs in diseases with unmet medical needs. The Company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Applied Lipid Technologies Inc. (Formerly Altemia, Inc.). About Cynaptec Pharmaceuticals, Inc . Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary L-130 (psilocin mucate) compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders. Cynaptec is 64% owned by Lobe. About L-130 (psilocin mucate) L-130 is a novel, patented, oral, stable analog of psilocin, theactive metabolite of the prodrugpsilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions. Whereas conventional psilocin is an unstable compound that has been challenging for the industry to develop as a standalone pharmaceutical, L-130's stability and bioavailability profile, and associated safety and efficacy signals, suggest the potential for prescription drug development in a variety of neurological and psychiatric indications. For Further Information Dr. Frederick D. Sancilio Chief Executive Officer Lobe Sciences Ltd. Email: [email protected] Phone: +1 (949) 505-5623 Website: www.lobesciences.com Cautionary Statement Regarding "Forward-Looking" Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statem